Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids

Cunningham, Rodat T.; Pogue, Kathy M.; Curry, William; Johnston, C.F.; Sloan, James M.; Buchanan, K. D.

doi:10.1002/(sici)1096-9896(199902)187:3<321::aid-path258>3.3.co;2-0

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the EL35 peptide is present in the adult human adrenal gland, it can be hypothesized that the processing of this peptide is altered in tumorous tissue. It has been recently shown that the immunoreactivity of the N-terminal portion of CgA (VS I) can discriminate metastatic deposits of ileum or lung carcinoids (Cunningham et al 1999). Similarly, the concentration of the SgII-derived peptide SN is markedly increased in endocrine tumors such as gut carcinoids, endocrine pancreatic tumors, lung carcinomas, and pheochromocytomas, but not in neuroblastomas, insulinomas, pituitary adenomas, and non-endocrine tumors (Ischia et al 2000).…”

Section: Discussionmentioning

confidence: 97%

Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands

Montero-Hadjadje

Vaudry

Turquier

et al. 2002

Cell and Tissue Research

View full text Add to dashboard Cite

Chromogranin A (CgA) is a neuroendocrine protein that undergoes proteolytic cleavage in secretory granules. The aim of the present study was to characterize the peptides WE14 and EL35 that are derived from evolutionarily conserved regions of CgA in rat and human endocrine tissues. In the rat pituitary, HPLC analysis revealed that WE14 is present as a single immunoreactive peak, whereas EL35 elutes in two molecular forms. Authentic WE14 is also produced in both rat and human adrenal glands, while EL35 displays a variable elution profile depending on the tissue extract, indicating the existence of different forms of EL35 in these tissues. Immunohistochemical labeling of the rat pituitary showed that WE14 and EL35 occur in gonadotropes and melanotropes, but not in corticotropes. A strong immunoreaction for both peptides was also observed in rat adrenochromaffin cells. In the human adrenal gland, the WE14 and EL35 antisera revealed intense labeling of adrenomedullary cells in adult and nests of chromaffin progenitor cells in fetal adrenal. Finally, WE14 and EL35 immunoreactivity was detected in pheochromocytoma tissue where WE14 occurred as a single immunoreactive form, while EL35 displayed different forms. The observations that WE14 and EL35: (1). have been preserved during vertebrate evolution, (2). are processed in a cell-specific manner, and (3). occur during ontogenesis of the adrenal gland strongly suggest that these peptides play a role in endocrine tissues. In addition, the existence of differentially processed CgA-derived peptides in normal and tumorous tissues may provide new tools for the diagnosis and prognosis of neuroendocrine tumors.

show abstract

Section: Discussionmentioning

confidence: 97%

Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands

Montero-Hadjadje

Vaudry

Turquier

et al. 2002

Cell and Tissue Research

View full text Add to dashboard Cite

show abstract

“…Different cleavage of a given CgA-derived peptide may also occur in a NET type, e.g., vasostatins in NETs of the lung, where Portela-Gomes et al (2005) reported that bronchial carcinoid tumors expressed the disulfide bridge part of vasostatin-I (CgA17-38) whereas Cunningham et al (1999) showed that the C-terminus of vasostatin-I (CgA68-76) was virtually absent in these tumors.…”

Section: Immunohistochemical Studiesmentioning

confidence: 99%

Immunohistochemical and Biochemical Studies with Region-Specific Antibodies to Chromogranins A and B and Secretogranins II and III in Neuroendocrine Tumors

2010

View full text Add to dashboard Cite

This short review deals with our investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. The immunohistochemical expression of different epitopes of the granin family of proteins varies in NE cells in normal human endocrine and non-endocrine organs and in NETs, suggesting post-translational processing. In most NETs one or more epitopes of the granins were lacking, but variations in the expression pattern occurred both in benign and malignant NETs. A few epitopes displayed patterns that may be valuable in differentiating between benign and malignant NET types, e.g., well-differentiated NET types expressed more CgA epitopes than the poorly differentiated ones and C-terminal secretoneurin visualized a cell type related to malignancy in pheochromocytomas. Plasma concentrations of different epitopes of CgA and CgB varied. In patients suffering from carcinoid tumors or endocrine pancreatic tumors the highest concentrations were found with epitopes from the mid-portion of CgA. For CgB the highest plasma concentrations were recorded for the epitope 439-451. Measurements of SgII showed that patients with endocrine pancreatic tumors had higher concentrations than patients with carcinoid tumors or pheochromocytomas. SgIII was not detectable in patients with NETs.

show abstract

“…Classically, these markers are cytosolic (NSE, PGP9.5) or associated with small, clear vesicles (synaptophysin) or secretory neuroendocrine granules (chromogranins, Leu7, 7B2) [3,4,6,30]. However, there is still a need for identifying markers with prognostic significance and/or suitable for distinguishing between different types of neuroendocrine tumours, especially when encountered in metastatic sites [1,5,7,8,11,17,21,22,24,26,34].…”

Section: Introductionmentioning

confidence: 99%

CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours

et al. 2000

View full text Add to dashboard Cite

Although considered a specific marker for Ewing's sarcoma/peripheral neuroectodermal tumour, the MIC2 gene product (CD99) has been immunolocalised in a variety of human tumours. The present study evaluated immunohistochemically the prevalence of CD99 expression in a series of 68 neuroendocrine tumours of different gastrointestinal and pulmonary sites. We now report on membrane and/or granular cytoplasmic immunoreactivity in 25% of these tumours, independent of their anatomical sites. In lung neuroendocrine tumours, CD99 was preferentially confined to typical carcinoids (P=0.009). A statistically significant relationship was observed between the number of CD99 positive cells but not the immunostaining patterns and the presence of local invasion and/or distant metastases (P<0.001). Moreover, there was a tendency for CD99-reactive tumours to show a reduced proliferative activity expressed by a Ki67 index of 2% (P=0.119). The number of CD99 immunoreactive cells or patterns of immunoreactivity did not correlate with the presence of associated clinical syndrome or particular hormonal immunostaining. Although the molecular basis underlying CD99 expression in neuroendocrine tumours is still poorly understood, our data suggest that CD99 may be involved in cell-to-cell adhesion of neuroendocrine tumour cells and in downregulation of their proliferative activity.

show abstract

Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids

Cited by 5 publications

References 0 publications

Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands

Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands

Immunohistochemical and Biochemical Studies with Region-Specific Antibodies to Chromogranins A and B and Secretogranins II and III in Neuroendocrine Tumors

CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours

Contact Info

Product

Resources

About